vimarsana.com
Home
Live Updates
Aura Biosciences Reports Third Quarter 2023 Financial Result
Aura Biosciences Reports Third Quarter 2023 Financial Result
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Received FDA Agreement Under Special Protocol Assessment for the CoMpass Phase 3 Clinical Trial
Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing...
Related Keywords
United States ,
Boston ,
Massachusetts ,
Mark Plavsic ,
Los Pinos ,
J Jill Hopkins ,
Technology Officer ,
Company Phase ,
Exchange Commission ,
Twitter ,
Exploratory Development At Novartis ,
Novartis Company ,
Linkedin ,
Nasdaq ,
Aura Biosciences Inc ,
Oncology Division ,
Company Global Phase ,
Aura Biosciences ,
Elisabet De Los Pinos ,
Chief Executive Officer ,
Compass Phase ,
Fast Track Designation ,
Gross Proceeds ,
Chief Medical Officer ,
Senior Vice President ,
Global Head ,
Exploratory Development ,
Gyroscope Therapeutics ,
Chief Technology ,
Chief Technology Officer ,
Fate Therapeutics ,
Global Phase ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Report ,
Comprehensive Loss ,
Markets ,